**+ +**

# *cis***-[Pt(NH3)2(9-MeA-***N7***)(9-EtGH-***N7***)](PF6)2**'**1.5H2O**  $(9\text{-MeA} = 9\text{-Methyladenine; } 9\text{-EtGH} =$ **9-Ethylguanine): A Right-Handed Helicoidal Model Compound for the Intrastrand A,G Cross-Link in Duplex DNA**

## **Guy Schro**1**der,1a Michal Sabat,1b Ivan Baxter,1c Jirı**´ **Kozelka,1d and Bernhard Lippert\*,1a**

Fachbereich Chemie, Universität Dortmund, D-44221 Dortmund, Germany, Department of Chemistry, University of Virginia, Charlottesville, Virginia 22901, and Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, URA 400 CNRS, Université René Descartes, F-75270 Paris Cedex 06, France

*Recei*V*ed September 12, 1996*

#### **Introduction**

Very recently we described the synthesis, crystal structure, and conformational analysis of a model nucleobase complex,  $cis$ -[Pt(NH<sub>3</sub>)<sub>2</sub>(9-MeA-*N7*)(9-EtGH-*N7*)](NO<sub>3</sub>)<sub>2</sub>·2H<sub>2</sub>O (9-MeA = 9-methyladenine;  $9$ -EtGH  $=$  9-ethylguanine), which we considered a model compound for an intrastrand adduct of the antitumor compound cisplatin between adjacent adenine and guanine nucleobases in DNA.2 Cross-linking between these two bases, in the 5′ApG sequence, is the second most abundant mode of cisplatin binding to DNA and accounts for ca.  $20-30\%$  of all Pt adducts.3 A detailed conformational analysis led to the conclusion that the orientation of the two purine bases in this model compound corresponds to a situation encountered in the minor rotamer form of *cis*-[(NH<sub>3</sub>)<sub>2</sub>Pt{d(ApG)}]<sup>+</sup> and probably relevant to this adduct in single-stranded DNA.2 Being aware of the fact that, in model nucleobase complexes, counterions sometimes are crucial in stabilizing different conformers<sup>4</sup> or rotamers,<sup>5</sup> we have successfully crystallized the above model compound, as the  $PF_6^-$  salt, in which the nucleobases assume the right-handed orientation R2 relevant to cisplatin-d(ApG) adducts of double-stranded DNA. Because the crystal system is centrosymmetric, the enantiomeric conformation L2 is present in the crystal as well. As it turned out, the  $PF_6^-$  salt crystallizes with two independent cations which differ slightly as far as dihedral and torsional angles are concerned.

### **Experimental Section**

**Synthesis of** *cis***-[Pt(NH3)2(9-MeA-***N7***)(9-EtGH-***N7***)](PF6)2**'**1.5H2O (1).** Compound **1** was obtained upon anion exchange (Merck, type II) from *cis*-[Pt(NH3)2(9-MeA-*N7*)(9-EtGH-*N7*)](NO3)2'2H2O, which was prepared as described previously.2 A 281 mg sample (0.392 mmol) of *cis*-[Pt(NH3)2(9-MeA-*N7*)(9-EtGH-*N7*)](NO3)2'2H2O was dissolved in 3 mL of water, and the solution was placed on the column. Elution of **1** was carried out with 150 mL of water. The resulting solution was reduced to a volume of 4 mL by rotary evaporation and stored at 4 °C.

- (1) (a) Universität Dortmund. (b) University of Virginia. (c) Participant of the Research Experience for Undergraduates Program, University of Virginia. Present address: Goucher College, Baltimore, MD 21204. (d) Université René Descartes.
- (2) Schröder, G.; Kozelka, J.; Sabat, M.; Fouchet, M.-H.; Beyerle-Pfnür, R.; Lippert, B. *Inorg*. *Chem*. **1996**, *35*, 1647.
- (3) (a) Fichtinger-Schepman, A. M. J.; van der Veer, J. L.; den Hartog, J. H. J.; Lohman, P. H. M.; Reedijk, J. *Biochemistry* **1985**, *24*, 707. (b) Eastman, A. *Pharmacol*. *Ther*. **1987**, *34*, 155 and references cited.
- (4) Schöllhorn, H.; Raudaschl-Sieber, G.; Müller, G.; Thewalt, U.; Lippert, B. *J*. *Am*. *Chem*. *Soc*. **1985**, *107*, 5932.
- (5) Holthenrich, D.; Sóvágó, I.; Fusch, G.; Erxleben, A.; Fusch, E. C.; Rombeck, I.; Lippert, B. *Z*. *Naturforsch*. **1995**, *50B*, 1767.

**Table 1.** Crystallographic Data for *cis*-[Pt(NH3)2(9-MeA-*N7*)(9-EtGH-*N7*)](PF6)2'1.5H2O (**1**)



**1** was obtained in 42% yield. Anal. Calcd for C13H25N12O2.5P2F12Pt: C, 17.9; H, 2.9; N, 19.2. Found: C, 17.8; H, 3.1; N, 19.9.

**Synthesis of** *cis***-[Pt(NH3)2(9-MeA-***N7***)(9-EtG-***N7***)]NO3**'**0.5H2O (2).** A 100 mg sample of *cis*-[Pt(NH3)2(9-MaA-*N7*)(9-EtGH-*N7*)]-  $(NO<sub>3</sub>)<sub>2</sub>·2H<sub>2</sub>O$  added to 10 mL of a 0.029 M NaOH solution was heated to 90 °C during 30 min. The reaction mixture was then filtered, and the filtrate was kept in a closed flask at 4 °C. The precipitated product was filtered off and dried at 40 °C. The yield was 54%. Anal. Calcd for C13H22N13O4.5Pt: C, 24.9; H, 3.5; N, 29.0. Found: C, 24.8; H, 3.3; N, 28.7.

<sup>1</sup>H NMR Spectroscopy. <sup>1</sup>H NMR spectra were recorded on a Bruker AC200 spectrometer (200 MHz) in DMSO- $d_6$  using the signal of nondeuterated DMSO as internal reference ( $\delta = 2.50$  ppm relative to TMS).

**X-ray Crystallography.** X-ray measurements were carried out on a Rigaku AFC6S diffractometer using Mo K $\alpha$  radiation ( $\lambda = 0.710$  69 Å). Calculations were performed on a VAXstation 3500 computer using TEXSAN 5.0 software<sup>6</sup> and in the later stage on a Silicon Graphics Personal Iris 4D35 computer with the teXsan 1.7 package.<sup>7</sup>

Relevant crystallographic data are listed in Table 1. Unit cell dimensions were determined by applying the setting angles of 25 highangle reflections. Three standard reflections monitored during the data collection showed no significant variance. The intensities were corrected for absorption by applying the DIFABS program<sup>8</sup> with the transmission factors in the range  $0.77-1.32$ .

The structure was solved by direct methods in SIRR88.9 Full-matrix least-squares refinement was carried out with anisotropic thermal displacement parameters for the Pt, P, and F atoms. The final difference Fourier map revealed a 2.11 e/ $\AA$ <sup>3</sup> peak located in the vicinity of the Pt2 atom.

#### **Results and Discussion**

One of the two crystallographically independent cations of  $cis$ -[Pt(NH<sub>3</sub>)<sub>2</sub>(9-MeA-*N7*)(9-EtGH-*N7*)](PF<sub>6</sub>)<sub>2</sub>·1.5H<sub>2</sub>O (1) is shown in Figure 1. The second cation is very similar (Supporting Information). In both cations the purine nucleobases

- (7) *teXsan 1.7: Single Crystal Structure Analysis Software*, Molecular Structure Corp.: The Woodlands, TX 77381, 1995.
- (8) Walker, N.; Stuart, D. *Acta Crystallogr*.*, Sect*. *A* **1983**, *39*, 158.
- (9) Burla, M. G.; Camalli, M.; Cascarano, G.; Giacovazzo, C.; Polidori, G.; Spagna, R.; Viterbo, D. *J*. *Appl*. *Crystallogr*. **1989**, *22*, 389.

<sup>(6)</sup> *TEXSAN 5.0: Single Crystal Structure Analysis Software*; Molecular Structure Corp.: The Woodlands, TX 77381, 1989.



**+ +**

**Figure 1.** View of one of two crystallographically independent cations of **1** with its atom labeling scheme. Thermal ellipsoids are 30% equiprobability envelopes.

**Table 2.** Conformational Angles  $\alpha$  and  $\beta$ , Dihedral Angles, and Intracomplex H-Bond Data for Enantiomers of *cis*-[Pt(NH3)2(9-MeA-*N7*)(9-EtGH-*N7*)]2<sup>+</sup> (Head-Head)*<sup>a</sup>*

$\alpha$ , deg	$\beta$ , deg	conformul domain	9-MeA/9-EtGH, deg	$O6G\cdots N6A$ .	ref
105 $-105$	$-45$ $+45$	HH1 (R2) HH2(L2)	87.5	3.37	h
115 $-115$	$-48$ $+48$	HH1 (R2) HH2(L2)	81.8	3.23	h
$+66$ $-66$	$-88$ $+88$	HH1(L1) HH2(R1)	92.1	3.11	$\mathcal{P}$

*a* See ref 10 for the definition of  $\alpha$  and  $\beta$  and for the designation of the conformational domains. *<sup>b</sup>* This work.



**Figure 2.** Calculated energy map for *cis*-[Pt(NH<sub>3</sub>)<sub>2</sub>(9-MeA-*N7*)(9-EtGH-*N7*)]<sup>2+</sup>.  $\diamondsuit = \alpha$ ,  $\beta$  coordinates of the NO<sub>3</sub><sup>-</sup> salt;  $\blacklozenge = \alpha$ ,  $\beta$ coordinates of the two cations of the  $PF_6^-$  salt. For other details see Figure 5 in ref 2.

are platinated at their respective N7 positions, consistent with the method of preparation, and the two bases adopt a headhead orientation. Except for torsional angles  $\alpha$  and  $\hat{\beta}$ ,<sup>10</sup> dihedral base/base angles, and intracomplex O6G ··· N6A hydrogen bonds (Table 2), other geometrical parameters (nucleobase geometries; Pt coordination spheres) of  $NO<sub>3</sub><sup>-</sup>$  and  $PF<sub>6</sub><sup>-</sup>$  salts are rather similar. Both chiral cations have the respective enantiomers present in the crystal. The principal difference between the cations of the  $\overline{NO_3}^-$  salt and the two variants of the  $\overline{PF_6}^-$  salt orignates from the combination of  $\alpha$  and  $\beta$  angles (Figure 2) and the resulting helicities of the cations (Table 2). The values of  $\alpha$  and  $\beta$  for the cations of the PF<sub>6</sub><sup>-</sup> salt are in the low-energy zones calculated by molecular mechanics methods for *cis*-[Pt-

#### Notes *Inorganic Chemistry, Vol. 36, No. 3, 1997* **491**

 $(NH_3)_2 (Ade) (Gua) ]^{2+}$ <sup>2</sup> As we have argued previously,<sup>2</sup> the enantiomer of *cis*-[Pt(NH<sub>3</sub>)<sub>2</sub>(9-MeA- $N7$ )(9-EtGH- $N7$ )](NO<sub>3</sub>)<sub>2</sub> having negative  $\alpha$  and positive  $\beta$  values (i.e., belonging to the HH2 zone) is close to the conformational domain of the minor rotamer of *cis*-[Pt(NH<sub>3</sub>)<sub>2</sub>{d(ApG)}]<sup>+</sup> (solid-line square in Figure 2) and can therefore be considered a model for this rotamer. On the other hand, the two HH1 enantiomers of the  $PF_6^-$  salt with positive  $\alpha$  and negative  $\beta$  values are right-handed helicity are in the domain of the major rotamer of *cis*-[Pt(NH<sub>3</sub>)<sub>2</sub>- ${d(ApG)}$   $\}$ <sup>+</sup> (dotted square in Figure 2) and thus represent models thereof. Since the conformational domain around the "R2" energy minimum in the HH1 domain is also expected to be favored by duplex  $Pt-d(ApG)$  adducts,<sup>10</sup> the two HH1 enantiomers of the present crystal structure analysis should be considered models of the d(ApG) adducts of cisplatin in doublestranded DNA.

As compared to the guanine/guanine intrastrand cross-link, for which a number of model compounds have been studied both in the solid state<sup>11a-c,11f-h,12</sup> and in solution<sup>11d,e,13a-c</sup> little is known about the effect of the adenine/guanine adduct on DNA geometry and H bonding with the complementary strand. Available knowledge on this adduct is primarily based on biochemical<sup>14</sup> and mutagenicity<sup>15</sup> studies. Base substitution reactions observed in mutagenicity studies with *Escherchia coli*<sup>15</sup> suggest that distortion of the DNA helix is larger at the 5′-side, consistent with the T,A pair being inherently weaker than the G,C pair. The degree by which base platination affects the strengths of these pairs is unknown, however.

In order to obtain some qualitative insight into this question, we decided to study the H-bonding properties of our model compound with regard to 1-methylcytosine (1-MeC) by recording 1H NMR spectra of 1:1 mixtures of *cis*-[Pt(NH3)2(9-MeA- $N7$ )(9-EtGH- $N7$ )]<sup>2+</sup> and 1-MeC in DMSO- $d_6$ . Due to the general weakness of A,T pairing in this solvent, analogous work with 1-methylthymine proved inconclusive. A comparison with H bonding properties of free 9-EtGH and 1-MeC in the same solvent reveals an interesting difference: While, for 9-EtGH/ 1-MeC, interaction shifts<sup>16,17</sup> of guanine N1H and N2H<sub>2</sub> as well as cytosine N4H<sub>2</sub> are fully consistent with Watson-Crick pairing (viz., the guanine N1H resonance undergoes a concen-

- (10) Kozelka, J.; Fouchet, M.-H.; Chottard, J.-C. *Eur*. *J*. *Biochem*. **1992**, *205*, 895.
- (11) (a) Sherman, S. E.; Gibson, D.; Wang, A. H.-J.; Lippard, S. J. *Science* **1985**, *230*, 415. (b) Sherman, S. E.; Gibson, D.; Wang, A. H.-J.; Lippard, S. J. *J*. *Am*. *Chem*. *Soc*. **1988**, *110*, 7368. (c) Coll, M.; Sherman, S. E.; Gibson, D.; Lippard, S. J.; Wang, A. H.-J. *J*. *Biomol*. *Struct*. *Dyn*. **1990**, *8*, 315. (d) Girault, J. P.; Chottard, G.; Lallemand, J. Y.; Chottard, J. C. *Biochemistry* **1982**, *21*, 1352. (e) den Hartog, J. H. J.; Altona, C.; Chottard, J. C.; Girault, J. P.; Lallemand, J. Y.; de Leeuw, F. A. A. M.; Marcelis, A. T. M.; Reedijk, J. *Nucleic Acids Res*. **1982**, *10*, 4715. (f) Admiraal, G.; van der Veer, J. L.; de Graff, R. A. G.; den Hartog, J. H. J.; Reedijk, J. *J*. *Am*. *Chem*. *Soc*. **1987**, *109*, 592. (g) Lippert, B.; Raudaschl, G.; Lock, C. J. L.; Pilon, P. *Inorg. Chim. Acta* **1984**, 93, 43. (h) Schöllhorn, H.; Raudaschl-Sieber, G.; Mu¨ller, G.; Thewalt, U.; Lippert, B. *J*. *Am*. *Chem*. *Soc*. **1985**, *107*, 5932.
- (12) Takahara, P. M.; Rosenzweig, A. C.; Frederick, C. A.; Lippard, S. J. *Nature* **1995**, *377*, 649.
- (13) (a) den Hartog, J. H. J.; Altona, C.; van Boom, J. H.; van der Marel, G. A.; Haasnoot, C. A. G.; Reedijk, J. *J*. *Biomol*. *Struct*. *Dyn*. **1985**, *2*, 1137. (b) Herman, F.; Kozelka, J.; Stoven, V.; Guittet, E.; Girault, J. P.; Huynh-Dinh, T.; Igolen, J.; Lallemand, J. Y.; Chottard, J. C. *Eur*. *J*. *Biochem*. **1990**, *194*, 119. (c) Yang, D.; van Boom, S. S. G. E.; Reedijk, J.; van Boom, J. H.; Wang, A. H. J. *Biochemistry* **1995**, *34*, 12912.
- (14) See, e.g.: (a) Corda, Y.; Anin, M.-F.; Leng, M.; Job, D. *Biochemistry* **1992**, *31*, 1904. (b) Corda, Y.; Anin, M.-F.; Leng, M.; Job, D. *Biochemistry* **1991**, *30*, 222. (c) Schwartz, A.; Marrot, L.; Leng, M. *Biochemistry* **1989**, *28*, 7975.
- (15) (a) Burnouf, D.; Daune, M.; Fuchs, R. P. P. *Proc*. *Natl*. *Acad*. *Sci*. *U*.*S*.*A*. **1987**, *84*, 3758. (b) Burnouf, D.; Gauthier, C.; Chottard, J. C.; Fuchs, R. P. P. *Proc*. *Natl*. *Acad*. *Sci*. *U*.*S*.*A*. **1990**, *87*, 6087.

**+ +**



Figure 3. Concentration dependent interaction shifts of selected <sup>1</sup>H NMR resonances (DMSO- $d_6$ , 20 °C) of (a) equimolar mixtures of 9-EtGH (GH) and 1-MeC (C) and (b) equimolar mixtures of  $1(A =$ 9-methyladenine, GH = 9-ethylguanine) and 1-MeC (C).  $\Delta \delta$  values in (a) account for self-association of GH. There is no detectable selfassociation of **1** in the absence of 1-MeC. Note the differences in scales in  $(a)$  and  $(b)$ .

tration-dependent downfield shift that is roughly twice that of the  $NH_2$  resonances),<sup>18</sup> in the case of equimolar mixtures of *cis*-[Pt(NH<sub>3</sub>)<sub>2</sub>(9-MeA-*N7*)(9-EtGH-*N7*)]<sup>2+</sup> and 1-MeC, this is not observed (Figure 3). Absolute interaction shifts of the N1H of guanine are significantly reduced in the Pt complex, and both H5 and H6 resonances of the cytosine base are likewise shifted

(17) Lippert, B. *J*. *Am*. *Chem*. *Soc*. **1981**, *103*, 5691.



Figure 4. Schematic representation of four feasible ways (square, dotted square, number sign, asterisk) of association of Watson-Crick **1**'1-MeC entities that could account for additional H-bond formation between the NH<sub>2</sub> groups of guanine and cytosine.



**Figure 5.** Guanine-guanine H bonding (a) between **2** and 9-EtGH and (b) between **1** and **2**.

downfield. The adenine  $N6H<sub>2</sub>$  resonance is not affected by the presence of 1-MeC. While these findings appear to be inconsistent with a Watson-Crick pairing scheme between platinated guanine and free cytosine at first glance, we feel that they do not really rule it out, considering the following points:

<sup>(16)</sup> Downfield shifts ∆*δ* relative to indefinite dilution of resonance of one component in the presence of the other, with self-association at the same concentration taken into account. Cf. ref 17.

<sup>(18) (</sup>a) Shoup, R. R.; Miles, H. T.; Becker, L. D. *Biochem*. *Biophys*. *Res*. *Commun*. **1966**, *23*, 194. (b) Katz, L.; Pennan, S. *J*. *Mol*. *Biol*. **1966**, *15*, 220. (c) Newmark, R. A.; Cantor, C. R. *J*. *Am*. *Chem*. *Soc*. **1968**, *90*, 5010.

First, H bonding between a platinated guanine and a cytosine has been established to be still possible, both in model compounds19 and in a platinated DNA double-stranded dodecamer.12,13a-<sup>c</sup> Second, with the *trans* isomer of the title complex, *trans*-[Pt(NH<sub>3</sub>)<sub>2</sub>(9-MeA-*N7*)(9-MeGH-*N7*)]<sup>2+</sup>, H bonding with 1-MeC in DMSO solution is still largely consistent with the Watson-Crick scheme.<sup>20</sup> Third, with *cis*-[Pt(NH<sub>3</sub>)<sub>2</sub>- $(9-EtGH-N7)(1-MeC-N3)$ <sup>2+</sup> H bonding with free 1-MeC again is largely according to Watson and Crick, despite some loss in selectivity.<sup>17</sup> Two features could account for the observed interaction shifts (Figure 3b): (i) The *cis* orientation of the adenine base may, through stacking with guanine, affect the shift of the N1H of guanine, thereby counteracting the downfield shift of H bonding. The virtually identical chemical shifts of the guanine N1H proton in the two isomers (11.45 and 11.49 ppm,  $DMSO-d_6$ ) in the absence of 1-MeC do not support this assumption. (ii) An aggregation of platinated guanine and free cytosine beyond the level of pair formation might explain why guanine  $NH<sub>2</sub>$  and cytosine  $NH<sub>2</sub>$  interaction shifts increase relative to that of the N1H of guanine. It is well established that, in the solid state, Watson-Crick pairs between guanine and 8-bromocytosine associate via the still available second NH protons of the amino groups.<sup>21</sup> We tentatively consider this explanation to be more likely in our case. Accordingly, intermolecular H bonding of N7-platinated guanine increases at the expense of the normal Watson-Crick pair with cytosine. Concerning possible ways of association of  $cis$ -[Pt(NH<sub>3</sub>)<sub>2</sub>(9 $MeA-N7(9-EtGH-N7)[(NO<sub>3</sub>)<sub>2</sub>·1-MeC$  entities, a number of possible combinations are feasible (Figure 4), some of which could account for the effect of cytosine H5, for example (proximity of H5 and Pt with slightly propeller-twisted entities). No particular scheme can be favored at this point, however.

Deprotonation of **1** gives *cis*-[Pt(NH3)2Pt(9-MeA-*N7*)(9-EtG- $(N7)$ <sup> $\pm$ </sup> (2), which was isolated as its  $NO<sub>3</sub><sup>-</sup>$  salt. As compared to those of **1**, all 1H NMR resonances of **2** are shifted upfield (DMSO- $d_6$ ), as expected, with the N2H<sub>2</sub> of 9-EtG affected most strongly  $(+1.4$  ppm). By application of <sup>1</sup>H NMR spectroscopy, H bonding between **1** and **2** as well as between **2** and free 9-EtGH has been studied in solution. Strong H-bond formation between platinated, N1-deprotonated guanine and neutral guanine, platinated or unplatinated, is observed (Supporting Information), similar to the situation with  $cis$ -[Pt(NH<sub>3</sub>)<sub>2</sub>(1-MeC-*N3*)(9-EtG-*N7*)]<sup>+</sup>. <sup>17</sup> Interaction shifts indicate 3-fold guanine/ guanine H bonding as previously established by us using X-ray crystallography<sup>22,23</sup> and <sup>1</sup>H NMR spectroscopy.<sup>17</sup>

**Acknowledgment.** This work was supported by the Deutsche Forschungsgemeinschaft, the Fonds der Chemischen Industrie, and the Association pour la Recherche sur le Cancer (J.K.).

**Supporting Information Available:** Tables of positional parameters, thermal displacement parameters, and interatomic distances and angles, a view of the second cation, a stereoview of the unit cell, 1H NMR spectra of **1**'1-MeC, **2**, and **1**'**2**, and a plot of the concentration dependency of the interaction shifts of  $2 + 9$ -EtGH (20 pages). Ordering information is given on any current masthead page.

**+ +**

IC9611296 (19) Dieter-Wurm, I.; Sabat, M.; Lippert, B. *<sup>J</sup>*. *Am*. *Chem*. *Soc*. **<sup>1992</sup>**, *<sup>114</sup>*, 357.

<sup>(20)</sup> Schreiber, A.; Lüth, M. S.; Erxleben, A.; Fusch, E. C.; Lippert, B. *J. Am*. *Chem*. *Soc*. **1996**, *118*, 4124.

<sup>(21) (</sup>a) Sobell, H. M.; Tomita, K.; Rich, A. *Proc*. *Natl*. *Acad*. *Sci*. *U*.*S*.*A*. **1963**, *49*, 885. (b) Haschemeyer, A. E. V.; Sobell, H. M. *Acta Crystallogr*. **1965**, *19*, 125.

<sup>(22) (</sup>a) Faggiani, R.; Lock, C. J. L.; Lippert, B. *J*. *Am*. *Chem*. *Soc*. **1980**, *102*, 5418. (b) Faggiani, R.; Lippert, B.; Lock, C. J. L.; Speranzini, R. A. *Inorg*. *Chem*. **1982**, *21*, 3216.

<sup>(23)</sup> Schröder, G.; Lippert, B.; Sabat, M.; Lock, C. J. L.; Faggiani, R.; Song, B.; Sigel, H. *J*. *Chem*. *Soc*.*, Dalton Trans*. **1995**, 3767.